Immunological
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
The France-based giant inks a transaction potentially worth around $1.9bn to get hold of Dren Bio’s autoimmune disease treatment DR-0201.
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
In the crowded and competitive field of generalized myasthenia gravis, Amgen has faith that Uplizna’s twice-yearly administration will make it the treatment of choice.
Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
The proposed merger could consolidate a pipeline of immunology drug candidates at Alumis and was determined to offer better value than an unsolicited bid from Concentra.
The company has suffered a setback to its neuroscience asset, BHV-7000, and while its autoimmune disease candidate BHV-1300 is progressing, investors have their doubts.
The Belgian firm has posted a healthy set of financials for 2024, buoyed by strong uptake in the US across all indications for Bimzelx.
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
The company ended the year with financial momentum and will initiate clinical trials for its anti-TL1A in atopic dermatitis and MASH on top of late-stage studies ongoing in IBD.
CEO Paul Hudson has declared that “immunology is effectively our obesity” and the French firm is looking to use its position of strength in the space and its healthy cash pile to bring in early-stage assets.
CEO Djordje Filipovic tells Scrip that after talks with "multiple other potential partners,” the firm chose the Japanese group for its expertise and marketing capabilities in rare diseases” to be the licensing partner for tadekinig alfa in the US.
The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.
The FDA has approved the IL-23 inhibitor for Crohn's disease to add to its ulcerative colitis approval and put the drug in a position to compete with the likes of AbbVie's Skyrizi and Johnson & Johnson's Stelara.